Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm’s products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Analyst recommendations
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm’s products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Townsquare Capital LLC grew its position in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 28.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange ...
Private Trust Co. NA lifted its stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 81.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional ...
The Manufacturers Life Insurance Company trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 17.7% during the 3rd quarter, according to its most recent disclosure ...
In comparison, the Dow Jones Industrial Average rose 8 percent and the Nasdaq rose 6 percent, but the Nasdaq Biotech Index was in negative territory, falling by less than 1 percent.